Inhibiting integrin receptor binding with non-native monomeric disintegrin or monomeric disintegrin domains
This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop.
1. A method of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a peptide, which comprises the amino acid sequence as set forth in SEQ ID NO: 5.
2. The method of claim 1 wherein said integrin receptor is specific for the αvβ3 integrin.
3. The method of claim 1 , wherein said inhibiting, inhibits or decreases tumor metastasis and neovascularization in a cancer patient suffering from melanoma, carcinoma, or sarcoma.
4. The method of claim 1 , further comprising administering an effective amount of at least one thrombolytic agent to lyse thrombi.
5. The method of claim 4 , wherein said thrombolytic agent is selected from the group consisting of anisoylated plasminogen streptokinase activator complex (APSAC), tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA); and fibrolase.